+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Osteoporosis - Pipeline Review, H2 2018

  • ID: 4662955
  • Drug Pipelines
  • 273 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abreos Biosciences Inc
  • Cadila Healthcare Ltd
  • Entera Bio Ltd
  • GlycoNex Inc
  • Lupin Ltd
  • PhytoHealth Corp
  • MORE
Osteoporosis - Pipeline Review, H2 2018

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H2 2018, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

This latest pipeline guide Osteoporosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 6, 4, 21, 3, 56, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 12 and 12 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abreos Biosciences Inc
  • Cadila Healthcare Ltd
  • Entera Bio Ltd
  • GlycoNex Inc
  • Lupin Ltd
  • PhytoHealth Corp
  • MORE
Introduction

Osteoporosis - Overview

Osteoporosis - Therapeutics Development

Osteoporosis - Therapeutics Assessment

Osteoporosis - Companies Involved in Therapeutics Development

Osteoporosis - Drug Profiles

Osteoporosis - Dormant Projects

Osteoporosis - Discontinued Products

Osteoporosis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Osteoporosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Osteoporosis - Pipeline by Abreos Biosciences Inc, H2 2018

Osteoporosis - Pipeline by Alvogen Korea Co Ltd, H2 2018

Osteoporosis - Pipeline by Amgen Inc, H2 2018

Osteoporosis - Pipeline by Asahi Kasei Corp, H2 2018

Osteoporosis - Pipeline by BiosanaPharma BV, H2 2018

Osteoporosis - Pipeline by Biosion Inc, H2 2018

Osteoporosis - Pipeline by Bone Biologics Corp, H2 2018

Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H2 2018

Osteoporosis - Pipeline by Cadila Healthcare Ltd, H2 2018

Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H2 2018

Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Osteoporosis - Pipeline by Corium International Inc, H2 2018

Osteoporosis - Pipeline by Daewon Pharm Co Ltd, H2 2018

Osteoporosis - Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Osteoporosis - Pipeline by Dong Wha Pharma Co Ltd, H2 2018

Osteoporosis - Pipeline by Eli Lilly and Co, H2 2018

Osteoporosis - Pipeline by EndoCeutics Inc, H2 2018

Osteoporosis - Pipeline by Entera Bio Ltd, H2 2018

Osteoporosis - Pipeline by Enteris BioPharma Inc, H2 2018

Osteoporosis - Pipeline by Enzene Biosciences Ltd, H2 2018

Osteoporosis - Pipeline by Enzo Biochem Inc, H2 2018

Osteoporosis - Pipeline by Evgen Pharma Plc, H2 2018

Osteoporosis - Pipeline by Gador SA, H2 2018

Osteoporosis - Pipeline by Genor BioPharma Co Ltd, H2 2018

Osteoporosis - Pipeline by GL Pharm Tech Corp, H2 2018

Osteoporosis - Pipeline by GlycoNex Inc, H2 2018

Osteoporosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Osteoporosis - Pipeline by Haoma Medica Ltd, H2 2018

Osteoporosis - Pipeline by Huons Global Co Ltd, H2 2018

Osteoporosis - Pipeline by Immunwork Inc, H2 2018

Osteoporosis - Pipeline by Innovent Biologics Inc, H2 2018

Osteoporosis - Pipeline by InSight Biopharmaceuticals Ltd, H2 2018

Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H2 2018

Osteoporosis - Pipeline by Ipsen SA, H2 2018

Osteoporosis - Pipeline by JHL Biotech Inc, H2 2018

Osteoporosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Osteoporosis - Pipeline by Lead Discovery Center GmbH, H2 2018

Osteoporosis - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2018

List of Figures

Number of Products under Development for Osteoporosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abreos Biosciences Inc
  • Alvogen Korea Co Ltd
  • Amgen Inc
  • Asahi Kasei Corp
  • BiosanaPharma BV
  • Biosion Inc
  • Bone Biologics Corp
  • Bristol-Myers Squibb Co
  • Cadila Healthcare Ltd
  • ChoDang Pharm Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Corium International Inc
  • Daewon Pharm Co Ltd
  • Daiichi Sankyo Co Ltd
  • Dong Wha Pharma Co Ltd
  • Eli Lilly and Co
  • EndoCeutics Inc
  • Entera Bio Ltd
  • Enteris BioPharma Inc
  • Enzene Biosciences Ltd
  • Enzo Biochem Inc
  • Evgen Pharma Plc
  • Gador SA
  • Genor BioPharma Co Ltd
  • GL Pharm Tech Corp
  • GlycoNex Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Haoma Medica Ltd
  • Huons Global Co Ltd
  • Immunwork Inc
  • Innovent Biologics Inc
  • InSight Biopharmaceuticals Ltd
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • JHL Biotech Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Lead Discovery Center GmbH
  • Lotus Pharmaceutical Co Ltd
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • mAbxience SA
  • Merck & Co Inc
  • Millendo Therapeutics Inc
  • Nano Intelligent Biomedical Engineering Corp
  • Omeros Corp
  • Oncobiologics Inc
  • Paras Biopharmaceuticals Finland Oy
  • Pfenex Inc
  • PhytoHealth Corp
  • R Pharm
  • Reliance Life Sciences Pvt Ltd
  • Ribomic Inc
  • Richter Gedeon Nyrt
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • Shin Poong PharmCo Ltd
  • Sinil Pharmaceutical Co Ltd
  • Stelis Biopharma Pvt Ltd
  • Terpenoid Therapeutics Inc
  • TSH Biopharm Corporation Ltd
  • Uni-Bio Science Group Ltd
  • Viking Therapeutics Inc
  • ViroMed Co Ltd
  • Wroclawskie Centrum Badan EIT+ Sp z oo
  • Yooyoung Pharm Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4662955
Adroll
adroll